^
    Back
    Association details:
    Biomarker:EGFR S768I
    Cancer:Lung Adenocarcinoma
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib

    Excerpt:
    This case provides conclusive evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib. The in vivo emergence of EGFR T790M in the same allele confirms the selective pressure of erlotinib on the EGFR S768I mutant kinase.
    DOI:
    10.1097/JTO.0000000000000221